Investigation of interleukines-4, 6 and malondialdehyde levels in serum of Iraqi patients with chronic kidney diseases.

Q3 Medicine

Human Antibodies Pub Date : 2025-05-01 Epub Date: 2025-04-17 DOI:10.1177/10932607251322055

Marwa Al-Razak, Basima AlSaadi, Ali Al Saedi

{"title":"Investigation of interleukines-4, 6 and malondialdehyde levels in serum of Iraqi patients with chronic kidney diseases.","authors":"Marwa Al-Razak, Basima AlSaadi, Ali Al Saedi","doi":"10.1177/10932607251322055","DOIUrl":null,"url":null,"abstract":"BackgroundImmune dysfunction develops early in the course of renal failure in patients with chronic kidney disease and occurs independently of the underlying disease. Cytokines play an essential role in the control and regulation of the immune and inflammatory systems.ObjectiveThe current study aims to estimate Interleukin 4, Interleukin 6, and Malondialdehyde in the blood of Iraqi patients with chronic kidney disease.MethodsIn this study, 50 Iraqi chronic kidney disease patients (males 17 and females33) and 50 apparently healthy as the control group (male27 and females23) aged (20-65)years who attended lmamain Al-Kadhemain Medical Teaching Hospital and Al-Numan Hospital in Baghdad, Iraq. Interleukin 4, Interleukin 6, and malondialdehyde were measured using an enzyme-linked immunosorbent assay technique.ResultsThe serum level of IL-4 and IL-6 showed highly significant differences between chronic kidney disease patients and healthy control groups m as the mean value of both interleukin levels in patient groups was (25.524 ± 16.295, 12.844 ± 4.863) respectively, and mean of the control group (13.562 ± 7.488, 5.533 ± 2.970) respectively. The mean of malondialdehyde was (25.160 ± 17.152 and18.470 ± 6.545) in chronic kidney disease patients and control groups, respectively. There was a highly significant positive correlation between Interleukin6 and malondialdehyde (r = 0.862, P = 0.0001, r = 0.598, P = 0.0001), respectively. In addition, there was a highly significant positive correlation between Interleukin4 and malondialdehyde (r = 0.862, P = 0.0001, r = 0.662, P = 0.0001) respectively. There was a highly significant positive correlation between Interleukin 4 and Interleukin 6 (r = 0.598, P = 0.0001) and (r = 0.662, P = 0.0001) respectively.ConclusionsThe increased levels of Interleukin 4, Interleukin 6, and malondialdehyde are an indication of the progression in Iraqi patients with chronic kidney disease.","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":" ","pages":"40-47"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Antibodies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/10932607251322055","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

BackgroundImmune dysfunction develops early in the course of renal failure in patients with chronic kidney disease and occurs independently of the underlying disease. Cytokines play an essential role in the control and regulation of the immune and inflammatory systems.ObjectiveThe current study aims to estimate Interleukin 4, Interleukin 6, and Malondialdehyde in the blood of Iraqi patients with chronic kidney disease.MethodsIn this study, 50 Iraqi chronic kidney disease patients (males 17 and females33) and 50 apparently healthy as the control group (male27 and females23) aged (20-65)years who attended lmamain Al-Kadhemain Medical Teaching Hospital and Al-Numan Hospital in Baghdad, Iraq. Interleukin 4, Interleukin 6, and malondialdehyde were measured using an enzyme-linked immunosorbent assay technique.ResultsThe serum level of IL-4 and IL-6 showed highly significant differences between chronic kidney disease patients and healthy control groups m as the mean value of both interleukin levels in patient groups was (25.524 ± 16.295, 12.844 ± 4.863) respectively, and mean of the control group (13.562 ± 7.488, 5.533 ± 2.970) respectively. The mean of malondialdehyde was (25.160 ± 17.152 and18.470 ± 6.545) in chronic kidney disease patients and control groups, respectively. There was a highly significant positive correlation between Interleukin6 and malondialdehyde (r = 0.862, P = 0.0001, r = 0.598, P = 0.0001), respectively. In addition, there was a highly significant positive correlation between Interleukin4 and malondialdehyde (r = 0.862, P = 0.0001, r = 0.662, P = 0.0001) respectively. There was a highly significant positive correlation between Interleukin 4 and Interleukin 6 (r = 0.598, P = 0.0001) and (r = 0.662, P = 0.0001) respectively.ConclusionsThe increased levels of Interleukin 4, Interleukin 6, and malondialdehyde are an indication of the progression in Iraqi patients with chronic kidney disease.

查看原文本刊更多论文

伊拉克慢性肾病患者血清白介素-4、6和丙二醛水平的调查。

背景：免疫功能障碍在慢性肾病患者肾功能衰竭过程中早期出现，并且独立于基础疾病发生。细胞因子在控制和调节免疫系统和炎症系统中起着至关重要的作用。目的研究伊拉克慢性肾病患者血液中白细胞介素4、白细胞介素6和丙二醛的含量。方法选取在伊拉克巴格达Al-Kadhemain医学教学医院和Al-Numan医院就诊的50例（20 ~ 65岁）伊拉克慢性肾病患者（男17例，女33例）和50例明显健康的患者（男27例，女23例）作为对照组。使用酶联免疫吸附测定技术测定白细胞介素4、白细胞介素6和丙二醛。结果慢性肾脏病患者血清IL-4、IL-6水平与健康对照组差异显著，患者组血清IL-4、IL-6水平均值分别为（25.524±16.295,12.844±4.863），对照组血清IL-4、IL-6水平均值分别为（13.562±7.488,5.533±2.970）。慢性肾病患者和对照组丙二醛的平均值分别为（25.160±17.152）和（18.470±6.545）。白细胞介素6与丙二醛呈极显著正相关（r = 0.862, P = 0.0001, r = 0.598, P = 0.0001）。此外，白细胞介素4与丙二醛呈极显著正相关（r = 0.862, P = 0.0001, r = 0.662, P = 0.0001）。白细胞介素4与白细胞介素6呈极显著正相关（r = 0.598, P = 0.0001）和（r = 0.662, P = 0.0001）。结论白细胞介素4、白细胞介素6和丙二醛水平升高是伊拉克慢性肾病患者病情进展的一个指示。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Antibodies Medicine-Immunology and Allergy

CiteScore

3.50

自引率

0.00%

发文量

期刊介绍： Human Antibodies is an international journal designed to bring together all aspects of human hybridomas and antibody technology under a single, cohesive theme. This includes fundamental research, applied science and clinical applications. Emphasis in the published articles is on antisera, monoclonal antibodies, fusion partners, EBV transformation, transfections, in vitro immunization, defined antigens, tissue reactivity, scale-up production, chimeric antibodies, autoimmunity, natural antibodies/immune response, anti-idiotypes, and hybridomas secreting interesting growth factors. Immunoregulatory molecules, including T cell hybridomas, will also be featured.